Royalty Pharma (RPRX) Total Liabilities (2019 - 2026)

Royalty Pharma has disclosed Total Liabilities across 8 years of filings, most recently posting $9.9 billion for Q1 2026.

• Total Liabilities for Q1 2026 came in at $9.9 billion, up 26.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.9 billion (up 26.33% YoY), and the FY2025 annual result was $9.9 billion, up 25.7% from the prior year.
• Total Liabilities came in at $9.9 billion for Q1 2026 at Royalty Pharma, roughly flat from $9.9 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $9.9 billion in Q4 2025 to a low of $6.3 billion in Q1 2024.
• The 5-year median for Total Liabilities is $7.3 billion (2022), against an average of $7.8 billion.
• Across the five-year window, Total Liabilities fell 13.59% in 2023 and grew 26.33% in 2026, its largest moves.
• Royalty Pharma's Total Liabilities stood at $7.3 billion in 2022, then dropped by 13.59% to $6.3 billion in 2023, then rose by 25.13% to $7.9 billion in 2024, then rose by 25.7% to $9.9 billion in 2025, then slipped by 0.28% to $9.9 billion in 2026.
• The last three Total Liabilities figures came in at $9.9 billion (Q1 2026), $9.9 billion (Q4 2025), and $9.7 billion (Q3 2025), per Business Quant data.